Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2026 16:15 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and...
April 16, 2026 04:00 ET | Source: Alethio Therapeutics

Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND

Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a...
April 15, 2026 07:00 ET | Source: Beeline Medicines Corporation

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead program afimetoran, a potential...
April 15, 2026 07:00 ET | Source: Aerska

Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain

Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&DLisa Taylor Ash joins Board of Directors,...
April 15, 2026 02:00 ET | Source: Aerska

Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain

Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&DLisa Taylor Ash joins Board of Directors,...
April 14, 2026 22:38 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...
April 14, 2026 09:30 ET | Source: Culture Biosciences

Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth

SAN FRANCISCO, CALIFORNIA, UNITED STATES, April 14, 2026 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected bioprocess development technologies, today announced the appointment of...
April 14, 2026 09:00 ET | Source: Helical

Helical raises $10M for virtual AI lab that operates at pharma scale to make in-silico discovery reproducible

Helical is the virtual AI lab for pharma, designed to turn bio foundation models into reproducible discovery systems.
April 14, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting

Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104 Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T...
April 14, 2026 02:00 ET | Source: PannTheraPi

PannTheraPi Announces Significant Clinical Development and Strategic Milestones

PannTheraPi files Phase 2a trial for epilepsy drug PTI5803, secures EU patent, and appoints Sophie Binay as GM & CSO.